about
Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.Paris Polyphylla-Derived Saponins Inhibit Growth of Bladder Cancer Cells by Inducing Mutant P53 Degradation While Up-Regulating CDKN1A Expression.USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells.Insights of Crosstalk between p53 Protein and the MKK3/MKK6/p38 MAPK Signaling Pathway in Cancer.Comprehensive and integrative analysis identifies microRNA-106 as a novel non-invasive biomarker for detection of gastric cancer.Association of mRNA expression of TP53 and the TP53 codon 72 Arg/Pro gene polymorphism with colorectal cancer risk in Asian population: a bioinformatics analysis and meta-analysis.Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma.Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics.Good Guy or Bad Guy? The Duality of Wild-Type p53 in Hormone-Dependent Breast Cancer Origin, Treatment, and Recurrence.Ubiquitination by HUWE1 in tumorigenesis and beyondAssociation Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of GliomaNatural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicineInhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer CellsWild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism
P2860
Q47218594-3D865338-262B-4C05-9ED4-9C4AEAAF9014Q52579544-F2AD154E-125E-4949-B22A-03AF39C83EF3Q52716922-85944AA0-DCCB-40CB-87C7-285BF9D80881Q52723469-3E2D3913-8228-4B09-B6E7-5F1D1485A0C1Q54110522-565B5D29-7644-416D-B23A-8A0169097A13Q55010478-F2DB387B-1895-4BB7-95CD-8C14627A8489Q55217928-FDED3095-C1D1-4349-A407-270C6A595065Q55259197-EF003816-8A78-4A6B-9EE4-3DF20A8DA427Q55378109-F5F3BFB3-5A35-439C-9F43-366FB55CF52AQ55471290-2C2A3262-B60C-420B-B4C4-9A96693CEA1EQ55515610-2ED3E1D2-5E90-4157-8339-0ABE206F9409Q57161316-0BB567B8-942B-4DB8-8707-DA3AEA35D5A2Q57491541-C845706D-4E0C-4EBE-9400-340CF72F9DBEQ57496075-0B573ADD-7A33-4BB2-AE17-B79BBDAECC89Q58714397-DD81F82F-5072-4D19-8FFC-3CDE8075F76FQ58761640-60765001-779C-45C7-AD3C-2C85F703B99AQ58789576-5D7EE732-1F29-498C-B192-E05E4714D939
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Targeting mutant p53 for efficient cancer therapy.
@en
Targeting mutant p53 for efficient cancer therapy.
@nl
type
label
Targeting mutant p53 for efficient cancer therapy.
@en
Targeting mutant p53 for efficient cancer therapy.
@nl
prefLabel
Targeting mutant p53 for efficient cancer therapy.
@en
Targeting mutant p53 for efficient cancer therapy.
@nl
P2093
P356
P1476
Targeting mutant p53 for efficient cancer therapy
@en
P2093
Julie Bianchi
Sofi E Eriksson
Vladimir J N Bykov
P2888
P304
P356
10.1038/NRC.2017.109
P407
P50
P577
2017-12-15T00:00:00Z